{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=25", "query": { "intervention": "capecitabine", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T18:06:24.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02955940", "title": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Colorectal Cancer (CRC)", "Breast Cancer", "Lung Cancer" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-11-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 6, "location_summary": "Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Clifton Park", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955940" }, { "nct_id": "NCT02229149", "title": "Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Malignant Tumor of the Breast" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2014-12", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "Multiple Locations, Texas", "locations": [ { "city": "Multiple Locations", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02229149" }, { "nct_id": "NCT00967655", "title": "Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Loma Linda Oncology Medical Group, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 4, "location_summary": "Redlands, California", "locations": [ { "city": "Redlands", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00967655" }, { "nct_id": "NCT00235235", "title": "A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Serum Collection", "type": "PROCEDURE" }, { "name": "Urine Collection", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2005-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2015-12-09", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 10, "location_summary": "Bloomington, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 4 more", "locations": [ { "city": "Bloomington", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235235" }, { "nct_id": "NCT07456852", "title": "Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Digestive System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Diltiazem Hydrochloride", "type": "DRUG" }, { "name": "Electrocardiogram", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Holter Monitoring", "type": "DEVICE" }, { "name": "Isosorbide Mononitrate", "type": "DRUG" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-04-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07456852" }, { "nct_id": "NCT00026234", "title": "Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Liver Metastases", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "floxuridine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 75, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-16", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026234" }, { "nct_id": "NCT04336644", "title": "Continuous Versus Intermittent cARdiac Electrical moNitorinG", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Torsades de Pointe Caused by Drug", "Long QT Syndrome" ], "interventions": [ { "name": "BodyGuardian Mini Plus", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-11-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04336644" }, { "nct_id": "NCT01945775", "title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" }, { "name": "Physician's-Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2013-10-14", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 207, "location_summary": "Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945775" }, { "nct_id": "NCT01972919", "title": "MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Pancreatic Cancer" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Concurrent chemotherapy (Gemcitabine, Capecitabine)", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2015-12-10", "completion_date": "2026-06-11", "has_results": true, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972919" }, { "nct_id": "NCT00074321", "title": "Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-27T18:06:24.724Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074321" } ] }